Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa reported option exercises and share sales in the company’s Class A ordinary shares. On February 9, 2026, he exercised options for 8,374 shares at $12.97 and 2,471 shares at $16.90, converting them into the same number of shares.
On the same date, he sold 9,114 shares at a weighted average price of $42.85 and 8,731 shares at a weighted average price of $43.72 through a broker-dealer in multiple trades. These transactions were effected under a Rule 10b5-1 trading plan executed on August 14, 2025. After these trades, he directly held 12,086 Class A ordinary shares.
Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in early February 2026 under a pre-arranged trading plan. On February 2, 3, and 4, he exercised fully vested share options at an exercise price of $15.47 per Class A Ordinary Share and sold the resulting shares in open-market transactions at weighted average prices of $45.00, $45.27, and $45.02, respectively.
The transactions were effected pursuant to a Rule 10b5-1 plan executed on September 11, 2025. After these trades, he directly beneficially owned 12,546 Class A Ordinary Shares and 2,800 share options that are fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported equity compensation activity involving restricted share units and ordinary shares. On February 1, 2026, he received a grant of 683 Restricted Share Units, each representing the right to receive one Class A Ordinary Share.
The RSUs vested immediately upon grant on February 1, 2026 and had no expiration date. On the same date, 683 RSUs were settled, resulting in the acquisition of 683 Class A Ordinary Shares at a price of $0. Following these transactions, Levy directly owned 19,157 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc reported leadership changes effective January 10, 2026. The board appointed Ross Moat as chief operating officer and principal operating officer. He will keep overseeing commercial operations while taking on broader functional operations under the new title.
The board also appointed Eben Tessari as chief strategy officer, responsible for the company’s strategic, business development and technical operations, as well as its artificial intelligence initiatives. The company stated that there were no changes to the compensation arrangements for either executive in connection with these appointments.
Kiniksa Pharmaceuticals International, plc furnished an update on its 2025 financial performance. The company reported unaudited full-year 2025 ARCALYST net product revenue of $677.5 million. It also disclosed an unaudited gross-to-net figure of 8.4% for the year, indicating the difference between list prices and realized revenue after discounts and allowances. As of December 31, 2025, Kiniksa reported unaudited $414.1 million in cash, cash equivalents and short-term investments and stated that it had no debt. These figures were shared in a press release that is included as an exhibit.
Kiniksa Pharmaceuticals International, plc reported that its Chief Financial Officer, Mark Ragosa, sold 12,000 Class A ordinary shares on January 8, 2026. The sale was coded as an open-market disposition and was carried out at a weighted average price of $41.89 per share, through multiple trades within a disclosed price range. The transaction was completed under a pre-arranged Rule 10b5-1 trading plan that the reporting person executed on August 14, 2025, indicating the sale followed a preset schedule rather than ad hoc market timing. Following this transaction, the CFO directly beneficially owns 19,086 Class A ordinary shares of the company.
Kiniksa Pharmaceuticals International, plc director reports option exercise and share sale. On 12/15/2025, the reporting person exercised a share option for 20,129 Class A ordinary shares at an exercise price of $10.36 per share and acquired these shares. On the same date, they sold 20,129 Class A ordinary shares in broker-dealer trades at a weighted average price of $41.51 per share, with individual trade prices ranging from $41.19 to $41.78. After these transactions, the director beneficially owned 12,546 Class A ordinary shares directly, and held 0 derivative securities following the full exercise of the option, which was fully vested and exercisable. The transactions were made under a Rule 10b5-1 trading plan executed on September 11, 2025.
Kiniksa Pharmaceuticals International, plc reported an insider transaction by its Chief Operating Officer on 12/15/2025. The COO exercised an employee share option to acquire 6,000 Class A Ordinary Shares at an exercise price of $8.83 per share, then sold 12,048 Class A Ordinary Shares at a weighted average price of $41.56 per share through multiple trades.
After these transactions, the reporting person beneficially owned 16,666 Class A Ordinary Shares, held directly. The filing states that the trades were made under a pre-established Rule 10b5-1 trading plan executed on April 29, 2024, and notes that the option involved in this transaction was fully vested and exercisable.
Kiniksa Pharmaceuticals International, plc (KNSA) reported an insider equity transaction by its Chief Operating Officer on Form 4. On 11/17/2025, the COO exercised a share option for 6,500 Class A ordinary shares at an exercise price of $8.83 per share, then sold shares the same day in two broker-executed transactions under a pre-arranged Rule 10b5-1 trading plan dated April 29, 2024.
The sales included 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30, both executed in multiple trades within stated price ranges. After these transactions, the COO directly beneficially owned 22,714 Class A ordinary shares and held 6,000 share options that are fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA): The Chairman & CEO reported bona fide gifts (Code G) of Class A ordinary shares. On 11/12/2025, 111,794 shares were gifted; on 11/13/2025, 60,000 shares were gifted. These entries were at a stated price of $0 per share.
After the transactions, reported holdings were 0 shares direct, and indirect balances included 51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 shares held by The Patel Family Irrevocable Trust of 2025, and 109,795 shares held by The Marina 2016 Irrevocable Trust.